Abstract
Gemcitabine (2′-2′-difluorodeoxycytidine) is a well-known cytotoxic drug and a potent radio-enhancer. We herein report the in vitro evidence of its activity, and the clinical experiences when this drug is administered concurrently with radiation. The phase I-II trials are analyzed, focusing on the recent ability to deliver irradiation with low incidence of side effects. © 2006 Oxford University Press.
| Lingua originale | Inglese |
|---|---|
| pagine (da-a) | v52-v54 |
| Rivista | Annals of Oncology |
| Volume | 17 |
| DOI | |
| Stato di pubblicazione | Pubblicato - 2006 |
Keywords
- n/a